A Randomized, Open-label Phase Ib Trial of Fruquintinib "4mg Once Daily Continuous" Versus "5mg Once Daily 3wks on/1wk Off " in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy
Latest Information Update: 01 Mar 2019
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 10 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Results for the first stage presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 12 Nov 2013 New trial record